Loads of recommendations for approval from EMA's CHMP

30 January 2021

Following the January meetings of the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP), 10 recommendations for novel drugs, as well as two biosimilars and one generic, were issued

Among the positive opinions were two brands from Israel’s Teva Pharmaceutical Industries (NYSE: TEVA) Seffalair Spiromax (salmeterol/fluticasone) and its duplicate BroPair Spiromax (salmeterol/fluticasone) for the treatment of asthma in adults and adolescents aged 12 years and older.

The Committee recommended granting a marketing authorisation for Dutch firm Paion’s Byfavo (remimazolam) for procedural sedation.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK